Two new members named to the Board of Directors of the Ludwig Institute for Cancer Research

In January 2023, Jedd Wolchok and Nicolas Killen joined the Board of Directors of the Ludwig Institute for Cancer Research and the LICR Fund, which manages the assets of the Institute. Jedd is currently Meyer Director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine and co-director of the Ludwig Collaborative Laboratory at Weill Cornell Medicine, in New York. Nicolas is managing partner of the Geneva-based law firm Borel & Barbey. They replace Olivier Dunant, a partner at Borel & Barbey who joined the Board in 1998 and retired December 31, 2022; and Philip Pizzo, pediatric oncologist and David and Susan Heckerman Professor of Microbiology and Immunology, Emeritus, at Stanford University, who retired September 1, after eight years as a Board member. Nicolas, who has extensive experience in commercial and international tax law, received his initial law degree from Geneva University and earned an advanced degree in law (LLM) from Duke University. He joined Borel & Barbey in 1992 as an Associate, rising to Partner in 1999. A clinician-scientist and authority on cancer immunotherapy, Jedd has long been affiliated with Ludwig Cancer Research. He is a former Member of the Ludwig Institute, the former Lloyd J. Old/Virginia and Daniel K. Ludwig Chair in Clinical Investigation at Memorial Sloan Kettering Cancer Center (MSK) and former Director of the Ludwig Collaborative Laboratory at MSK.